China-based biopharmaceutical company Sinovac Biotech Limited said on Saturday that its unit's COVID-19 vaccine has been formally approved for use by the general public by China's medical products regulator. It marks the second COVID-19 vaccine green-lighted for public use in China, after a shot developed by a Beijing institute affiliated to state-owned China National Pharmaceutical Group (Sinopharm) was approved in December.

Both vaccines have already been used in China's vaccination program mainly targeting key groups deemed to be at higher risk of exposure to the virus.

Indonesia, Turkey, Brazil, Chile, Colombia, Uruguay, and Laos have granted emergency authorization for the CoronaVac vaccine developed by Sinovac Life Sciences, Sinovac said in a news release. Approval of the two-dose regimen by China's National Medical Products Administration is based on the results from two months of late-stage clinical trials overseas, from which the final analysis data has not yet been obtained, Sinovac said.

Sinovac Life Sciences is expected to be able to produce over 1 billion doses per year in the form of bulk ingredients by February, it said in a statement. It is expanding its capacity to fill vaccine into vials and syringes, which currently lags its vaccine manufacturing capacity.

Varied efficacy rates Sinovac's vaccine is being tested in Phase III clinical trials in countries including Brazil, Turkey and Indonesia, where varied efficacy readings had been released separately.

The vaccine was found 50.65% effective against COVID-19 disease in the Brazil trial which had recruited 12,396 health workers older than 18 as of December 16 and recorded 253 cases, Sinovac said in a statement on Friday.

Foreign Minister Jaishankar says, 'No effect of dialogue with China'

China to provide 500K doses of Covid-19 vaccine to Nepal

US warns of threats from China collecting Americans' health data